Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Januar 2020 16:15 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
08. Januar 2020 16:15 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
10. Dezember 2019 08:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting

NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
06. Dezember 2019 18:30 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
06. Dezember 2019 07:00 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
29. November 2019 13:05 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference

NEW YORK, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
07. November 2019 16:57 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.3 million for the third quarterNew patient starts estimated to have increased greater than 20% from last quarterConference call and live webcast scheduled for...
06. November 2019 09:15 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting

NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
05. November 2019 16:22 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
08. Oktober 2019 07:30 ET | Quelle: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

Vorherige Seite

Nächste Seite